Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

When DNA breaks, cells must repair it accurately to prevent harmful mutations. Researchers have discovered that during a key repair process called homologous recombination, the cell uses loops in its ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...

On December 12, 2025, the US Food and Drug Administration approved Johnson & Johnson subsidiary Janssen Biotech’s Akeega (niraparib and abiraterone acetate with prednisone for adults with deleterious ...

Scientists warn that the human Y chromosome has lost most of its genes over millions of years, and new research suggests ...